318 related articles for article (PubMed ID: 29771105)
1. Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital.
Del Rio-Valencia JC; Asensi-Diez R; Villalobos-Torres L; Muñoz Castillo I
Rev Esp Quimioter; 2018 Jun; 31(3):226-236. PubMed ID: 29771105
[TBL] [Abstract][Full Text] [Related]
2. Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital.
Del Rio-Valencia JC; Asensi-Diez R; Madera-Pajin R; Yunquera-Romero L; Muñoz-Castillo I
Rev Esp Quimioter; 2018 Feb; 31(1):35-42. PubMed ID: 29376623
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis.
Suwanthawornkul T; Anothaisintawee T; Sobhonslidsuk A; Thakkinstian A; Teerawattananon Y
PLoS One; 2015; 10(12):e0145953. PubMed ID: 26720298
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C.
Del Rio-Valencia JC; Asensi-Diez R; Tamayo-Bermejo R; Muñoz-Castillo I
Rev Esp Quimioter; 2019 Aug; 32(4):296-302. PubMed ID: 31232572
[TBL] [Abstract][Full Text] [Related]
6. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
[TBL] [Abstract][Full Text] [Related]
7. Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.
Naguib GG; Farid A; Hassan M; Elshafie A; Shazly YE; Shaker MK; Ezzat H; Safwat E; Ahmed OA; Dabbous H; Sherief AF; Hassany M; Elserafy M; Elsayed MH
Arab J Gastroenterol; 2021 Dec; 22(4):285-291. PubMed ID: 34531135
[TBL] [Abstract][Full Text] [Related]
8. Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.
Abdel-Moneim A; Aboud A; Abdel-Gabbar M; Zanaty M; Ramadan M
Dig Dis Sci; 2018 May; 63(5):1341-1347. PubMed ID: 29546644
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).
Shafran SD; Shaw D; Charafeddine M; Agarwal K; Foster GR; Abunimeh M; Pilot-Matias T; Pothacamury RK; Fu B; Cohen E; Cohen DE; Gane E
J Viral Hepat; 2018 Feb; 25(2):118-125. PubMed ID: 28833938
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
Dore GJ; Conway B; Luo Y; Janczewska E; Knysz B; Liu Y; Streinu-Cercel A; Caruntu FA; Curescu M; Skoien R; Ghesquiere W; Mazur W; Soza A; Fuster F; Greenbloom S; Motoc A; Arama V; Shaw D; Tornai I; Sasadeusz J; Dalgard O; Sullivan D; Liu X; Kapoor M; Campbell A; Podsadecki T
J Hepatol; 2016 Jan; 64(1):19-28. PubMed ID: 26321288
[TBL] [Abstract][Full Text] [Related]
11. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
Liver Int; 2016 Sep; 36(9):1275-83. PubMed ID: 26928927
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study.
Gaeta GB; Aghemo A; Menzaghi B; D'Offizi G; Giorgini A; Hasson H; Brancaccio G; Palma M; Termini R;
Medicine (Baltimore); 2018 Jul; 97(27):e11307. PubMed ID: 29979400
[TBL] [Abstract][Full Text] [Related]
13. Experience with direct-acting antivirals in genotype 1-5 infected chronic hepatitis C patients in Turkey.
Sahin A; Akay O
Ann Saudi Med; 2023; 43(5):308-314. PubMed ID: 37805816
[TBL] [Abstract][Full Text] [Related]
14. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.
Crespo J; Calleja JL; Fernández I; Sacristan B; Ruiz-Antorán B; Ampuero J; Hernández-Conde M; García-Samaniego J; Gea F; Buti M; Cabezas J; Lens S; Morillas RM; Salcines JR; Pascasio JM; Turnes J; Sáez-Royuela F; Arenas J; Rincón D; Prieto M; Jorquera F; Sanchez Ruano JJ; Navascués CA; Molina E; Moya AG; Moreno-Planas JM;
Clin Gastroenterol Hepatol; 2017 Jun; 15(6):945-949.e1. PubMed ID: 28238958
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia.
Alarfaj SJ; Alzahrani A; Alotaibi A; Almutairi M; Hakami M; Alhomaid N; Alharthi N; Korayem GB; Alghamdi A
Saudi Pharm J; 2022 Oct; 30(10):1448-1453. PubMed ID: 36387341
[TBL] [Abstract][Full Text] [Related]
16. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
Hlaing NKT; Nangia G; Tun KT; Lin S; Maung MZ; Myint KT; Kyaw AMM; Maung ST; Sein Win S; Bwa AH; Loza BL; Win KM; Reddy KR
J Viral Hepat; 2019 Oct; 26(10):1186-1199. PubMed ID: 31104344
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil.
Cheinquer H; Sette H; Wolff FH; de Araujo A; Coelho-Borges S; Soares SRP; Barros MFA
Ann Hepatol; 2017; 16(5):727-733. PubMed ID: 28809742
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.
Hlaing NKT; Mitrani RA; Aung ST; Phyo WW; Serper M; Kyaw AMM; Bwa AH; Win KM; Reddy KR
J Viral Hepat; 2017 Nov; 24(11):927-935. PubMed ID: 28475232
[TBL] [Abstract][Full Text] [Related]
19. High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results.
El Kassas M; Alboraie M; Omar H; El Latif YA; Algaber MA; El Tahan A; El Halwagy H; Afify S; Elserafy M; Elsaeed K; Doss W
J Med Virol; 2022 Feb; 94(2):667-674. PubMed ID: 30950069
[TBL] [Abstract][Full Text] [Related]
20. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.
Tao YC; Deng R; Wang ML; Lv DD; Yuan M; Wang YH; Chen EQ; Tang H
Virol J; 2018 Oct; 15(1):150. PubMed ID: 30285800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
